A Small Peptide with Therapeutic Potential for Inflammatory Acne Vulgaris

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Zhang, Zhiye ^a,c   Mu, Lixian ^a,c   Tang, Jing ^a,c   Duan, Zilei ^a,c   Wang, Fengyu ^b   Wei, Lin ^b   Rong, Mingqiang ^a   Lai, Ren ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b NANJING AGRICULTURAL UNIVERSITY   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI ACNE AGENT; CLINDAMYCIN; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VALYLLYSYLARGINYLTRYPTOPHYLLYSYLLYSYLTRYPTOPHYLTRYPTOPHYLARGINYLLYSYLTRYPTOPHYLLYSYLLYSYLTRYPTOPHYLVALINE AMIDE;

ACNE VULGARIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; HEMOLYSIS; HUMAN; HUMAN CELL; INFLAMMATION; INFLAMMATORY INFILTRATE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PROPIONIBACTERIUM ACNES;

ACNE VULGARIS; ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; HUMANS; INTERLEUKIN-1BETA; KERATINOCYTES; MICE; PEPTIDES; PROPIONIBACTERIUM ACNES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883336322     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072923     Document Type: Article

References (52)

1. Nakatsuji T, Kao MC, Fang JY, Zouboulis CC, Zhang L, et al. (2009) Antimicrobial property of lauric acid against Propionibacterium acnes: its therapeutic potential for inflammatory acne vulgaris. J Invest Dermatol 129: 2480-2488. doi:10.1038/jid.2009.93. PubMed: 19387482.
2. Williams HC, Dellavalle RP, Garner S, (2012) Acne vulgaris. Lancet 379: 361-372. doi:10.1016/S0140-6736(11)60321-8. PubMed: 21880356.
3. Webster GF, Leyden JJ, (1980) Characterization of serum-independent polymorphonuclear leukocyte chemotactic factors produced by Propionibacterium acnes. Inflammation 4: 261-269. doi:10.1007/BF00915027. PubMed: 7429606.
4. Burkhart CG, Burkhart CN, Lehmann PF, (1999) Acne: a review of immunologic and microbiologic factors. Postgrad Med J 75: 328-331. PubMed: 10435165.
5. Mourelatos K, Eady EA, Cunliffe WJ, Clark SM, Cove JH, (2007) Temporal changes in sebum excretion and propionibacterial colonization in preadolescent children with and without acne. Br J Dermatol 156: 22-31. doi:10.1111/j.1365-2133.2006.07517.x. PubMed: 17199562.
6. Iinuma K, Sato T, Akimoto N, Noguchi N, Sasatsu M, et al. (2009) Involvement of Propionibacterium acnes in the augmentation of lipogenesis in hamster sebaceous glands in vivo and in vitro. J Invest Dermatol 129: 2113-2119. doi:10.1038/jid.2009.46. PubMed: 19282842.
7. Vowels BR, Yang S, Leyden JJ, (1995) Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: implications for chronic inflammatory acne. Infect Immun 63: 3158-3165. PubMed: 7542639.
8. Nagy I, Pivarcsi A, Kis K, Koreck A, Bodai L, et al. (2006) Propionibacterium acnes and lipopolysaccharide induce the expression of antimicrobial peptides and proinflammatory cytokines/chemokines in human sebocytes. Microbes Infect 8: 2195-2205. doi:10.1016/j.micinf.2006.04.001. PubMed: 16797202.
9. Kim J, Ochoa MT, Krutzik SR, Takeuchi O, Uematsu S, et al. (2002) Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 169: 1535-1541. PubMed: 12133981.
10. Hoeffler U, (1977) Enzymatic and hemolytic properties of Propionibacterium acnes and related bacteria. J Clin Microbiol 6: 555-558. PubMed: 201661.
11. Hoeffler U, Ko HL, Pulverer G, (1976) Antimicrobiol susceptibility of Propionibacterium acnes and related microbial species. Antimicrob Agents Chemother 10: 387-394. doi:10.1128/AAC.10.3.387. PubMed: 984781.
12. Ingham E, Holland KT, Gowland G, Cunliffe WJ, (1980) Purification and partial characterization of an acid phosphatase (EC 3.1.3.2) produced by Propionibacterium acnes. J Gen Microbiol 118: 59-65. PubMed: 7420057.
13. Puhvel SM, Reisner RM, (1972) The production of hyaluronidase (hyaluronate lyase) by Corynebacterium acnes. J Invest Dermatol 58: 66-70. doi:10.1111/1523-1747.ep12551495. PubMed: 4258461.
14. Grange PA, Chéreau C, Raingeaud J, Nicco C, Weill B, et al. (2009) Production of superoxide anions by keratinocytes initiates P. acnes-induced inflammation of the skin. PLOS Pathog 5: e1000527. PubMed: 19629174.
15. Ozolins M, Eady EA, Avery AJ, Cunliffe WJ, Po AL, et al. (2004) Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomized controlled trial. Lancet 364: 2188-2195. doi:10.1016/S0140-6736(04)17591-0. PubMed: 15610805.
16. Gollnick H, Schramm M, (1998) Topical drug treatment in acne. Dermatology 196: 119-125. doi:10.1159/000017844. PubMed: 9557245.
17. Castro GA, Ferreira LA, (2008) Novel vesicular and particulate drug delivery systems for topical treatment of acne. Expert Opin Drug Deliv 5: 665-679. doi:10.1517/17425247.5.6.665. PubMed: 18532922.
18. Cunliffe WJ, Holland KT, Bojar R, Levy SF, (2002) A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 24: 1117-1133. doi:10.1016/S0149-2918(02)80023-6. PubMed: 12182256.
19. Swanson JK, (2003) Antibiotic resistance of Propionibacterium acnes in acne vulgaris. Dermatol Nurs 15: 359-362. PubMed: 14515616.
20. Böni R, Nehrhoff B, (2003) Treatment of gram-negative folliculitis in patients with acne. Am J Clin Dermatol 4: 273-276. doi:10.2165/00128071-200304040-00005. PubMed: 12680804.
21. Wang Y, Zhang Z, Chen L, Guang H, Li Z, et al. (2011) Cathelicidin-BF, a snake cathelicidin-derived antimicrobial peptide, could be an excellent therapeutic agent for acne vulgaris. PLOS ONE 6: e22120. doi:10.1371/journal.pone.0022120. PubMed: 21789223.
22. Li J, Xu X, Xu C, Zhou W, Zhang K, et al. (2007) Anti-infection peptidomics of amphibian skin. Mol Cell Proteomics 6: 882-894. doi:10.1074/mcp.M600334-MCP200. PubMed: 17272268.
23. Eichenfield LF, Wortzman M, (2009) A novel gel formulation of 0.25% tretinoin and 1.2% clindamycin phosphate: efficacy in acne vulgaris patients aged 12 to 18 years. Pediatr Dermatol 26: 257-261. doi:10.1111/j.1525-1470.2008.00862.x. PubMed: 19706084.
24. Abdel-Naser MB, Zouboulis CC, (2008) Clindamycin phosphate/tretinoin gel formulation in the treatment of acne vulgaris. Expert Opin Pharmacother 9: 2931-2937. doi:10.1517/14656566.9.16.2931. PubMed: 18937624.
25. Lu Y, Ma Y, Wang X, Liang J, Zhang C, et al. (2008) The first antimicrobial peptide from sea amphibian. Mol Immunol 45: 678-681. doi:10.1016/j.molimm.2007.07.004. PubMed: 17707909.
26. Lai R, Zheng YT, Shen JH, Liu GJ, Liu H, et al. (2002) Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima. Peptides 23: 427-435. doi:10.1016/S0196-9781(01)00641-6. PubMed: 11835991.
27. Yin LM, Edwards MA, Li J, Yip CM, Deber CM, (2012) Roles of hydrophobicity and charge distribution of cationic antimicrobial peptides in peptide-membrane interactions. J Biol Chem 287: 7738-7745. doi:10.1074/jbc.M111.303602. PubMed: 22253439.
28. Hwang H, Hyun S, Kim Y, Yu J, (2013) Reduction of helical content by insertion of a disulfide bond leads to an antimicrobial peptide with decreased hemolytic activity. Chem Med Chem 8: 59-62. PubMed: 23150226.
29. Graham GM, Farrar MD, Cruse-Sawyer JE, Holland KT, Ingham E, (2004) Proinflammatory cytokine production by human keratinocytes stimulated with Propionibacterium acnes and P. acnes GroEL. Br J Dermatol 150: 421-428. doi:10.1046/j.1365-2133.2004.05762.x. PubMed: 15030323.
30. Schaller M, Loewenstein M, Borelli C, Jacob K, Vogeser M, et al. (2005) Induction of a chemoattractive proinflammatory cytokine response after stimulation of keratinocytes with Propionibacterium acnes and coproporphyrin III. Br J Dermatol 153: 66-71. doi:10.1111/j.1365-2133.2005.06530.x. PubMed: 16029328.
31. Eady EA, Gloor M, Leyden JJ, (2003) Propionibacterium acnes resistance: a worldwide problem. Dermatology 206: 54-56. doi:10.1159/000067822. PubMed: 12566805.
32. Nord CE, Oprica C, (2006) Antibiotic resistance in Propionibacterium acnes. Microbiological and clinical aspects. Anaerobe 12: 207-210. doi:10.1016/j.anaerobe.2006.08.001. PubMed: 17000123.
33. Eady EA, Cove JH, Holland KT, Cunliffe WJ, (1989) Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 121: 51-57. doi:10.1111/j.1365-2133.1989.tb05952.x. PubMed: 2527056.
34. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, et al. (2003) Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 49: S1-37.
35. Leyden JJ, Preston N, Osborn C, Gottschalk RW, (2011) In-vivo Effectiveness of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel on Antibiotic-sensitive and Resistant Propionibacterium acnes. J Clin Aesthet Dermatol 4: 22-26. PubMed: 21607190.
36. Leyden JJ, Del Rosso JQ, Webster GF, (2007) Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis 79: 9-25. PubMed: 17649854.
37. Crawford WW, Crawford IP, Stoughton RB, Cornell RC, (1979) Laboratory induction and clinical occurrence of combined clindamycin and erythromycin resistance in Corynebacterium acnes. J Invest Dermatol 72: 187-190. doi:10.1111/1523-1747.ep12676385. PubMed: 429800.
38. Chronnell CM, Ghali LR, Ali RS, Quinn AG, Holland DB, et al. (2001) Human beta defensin-1 and-2 expression in human pilosebaceous units: upregulation in acne vulgaris lesions. J Invest Dermatol 117: 1120-1125. doi:10.1046/j.0022-202x.2001.01569.x. PubMed: 11710922.
39. Lee DY, Yamasaki K, Rudsil J, Zouboulis CC, Park GT, et al. (2008) Sebocytes express functional cathelicidin antimicrobial peptides and can act to kill propionibacterium acnes. J Invest Dermatol 128: 1863-1866. doi:10.1038/sj.jid.5701235. PubMed: 18200058.
40. Nizet V, (2006) Antimicrobial peptide resistance mechanisms of human bacterial pathogens. Curr Issues Mol Biol 8: 11-26. PubMed: 16450883.
41. Yeaman MR, Yount NY, (2003) Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 55: 27-55. doi:10.1124/pr.55.1.2. PubMed: 12615953.
42. Schibli DJ, Epand RF, Vogel HJ, Epand RM, (2002) Tryptophan-rich antimicrobial peptides: comparative properties and membrane interactions. Biochem Cell Biol 80: 667-677. doi:10.1139/o02-147. PubMed: 12440706.
43. Yang ST, Shin SY, Lee CW, Kim YC, Hahm KS, et al. (2003) Selective cytotoxicity following Arg-to-Lys substitution in tritrpticin adopting a unique amphipathic turn structure. FEBS Lett 540: 229-233. doi:10.1016/S0014-5793(03)00266-7. PubMed: 12681513.
44. Strøm MB, Rekdal O, Svendsen JS, (2002) Antimicrobial activity of short arginine- and tryptophan-rich peptides. J Pept Sci 8: 431-437. doi:10.1002/psc.398. PubMed: 12212806.
45. Park Y, Lee DG, Jang SH, Woo ER, Jeong HG, et al. (2003) A Leu-Lys-rich antimicrobial peptide: activity and mechanism. Biochim Biophys Acta 1645: 172-182. doi:10.1016/S1570-9639(02)00541-1. PubMed: 12573247.
46. Fimland G, Eijsink VG, Nissen-Meyer J, (2002) Mutational analysis of the role of tryptophan residues in an antimicrobial peptide. Biochemistry 41: 9508-9515. doi:10.1021/bi025856q. PubMed: 12135373.
47. Yau WM, Wimley WC, Gawrisch K, White SH, (1998) The preference of tryptophan for membrane interfaces. Biochemistry 37: 14713-14718. doi:10.1021/bi980809c. PubMed: 9778346.
48. Asthana N, Yadav SP, Ghosh JK, (2004) Dissection of antibacterial and toxic activity of melittin: a leucine zipper motif plays a crucial role in determining its hemolytic activity but not antibacterial activity. J Biol Chem 279: 55042-55050. doi:10.1074/jbc.M408881200. PubMed: 15475354.
49. Kondejewski LH, Jelokhani-Niaraki M, Farmer SW, Lix B, Kay CM, et al. (1999) Dissociation of antimicrobial and hemolytic activities in cyclic peptide diastereomers by systematic alterations in amphipathicity. J Biol Chem 7: 13181-13192. PubMed: 10224074.
50. Wang Y, Agerberth B, Löthgren A, Almstedt A, Johansson J, (1998) Apolipoprotein A-I binds and inhibits the human antibacterial/cytotoxic peptide LL-37. J Biol Chem 273: 33115-33118. doi:10.1074/jbc.273.50.33115. PubMed: 9837875.
51. Barańska-Rybak W, Sonesson A, Nowicki R, Schmidtchen A, (2006) Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids. J Antimicrob Chemother 57: 260-265. doi:10.1093/jac/dki460. PubMed: 16387752.
52. Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ, (2003) Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 121: 20-27. doi:10.1046/j.1523-1747.2003.12321.x. PubMed: 12839559.